Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
SEC Accession No. 0001013762-25-003583
Filing Date
2025-03-28
Accepted
2025-03-28 07:21:13
Documents
96
Period of Report
2024-09-30

Document Format Files

Seq Description Document Type Size
1 REPORT OF FOREIGN PRIVATE ISSUER ea0235714-6k_china.htm   iXBRL 6-K 18301
2 MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERA ea023571401ex99-1_china.htm EX-99.1 125665
3 UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS FOR THE SIX MONTHS ENDED S ea023571401ex99-2_china.htm   iXBRL EX-99.2 729511
4 GRAPHIC ex99-2_001.jpg GRAPHIC 50825
  Complete submission text file 0001013762-25-003583.txt   6692106

Data Files

Seq Description Document Type Size
5 XBRL SCHEMA FILE sxtc-20240930.xsd EX-101.SCH 75455
6 XBRL CALCULATION FILE sxtc-20240930_cal.xml EX-101.CAL 56927
7 XBRL DEFINITION FILE sxtc-20240930_def.xml EX-101.DEF 324214
8 XBRL LABEL FILE sxtc-20240930_lab.xml EX-101.LAB 575353
9 XBRL PRESENTATION FILE sxtc-20240930_pre.xml EX-101.PRE 345085
98 EXTRACTED XBRL INSTANCE DOCUMENT ea0235714-6k_china_htm.xml XML 780375
Mailing Address 178 TAIDONG ROAD NORTH TAIZHOU F4 225300
Business Address 178 TAIDONG ROAD NORTH TAIZHOU F4 225300 8652386298290
China SXT Pharmaceuticals, Inc. (Filer) CIK: 0001723980 (see all company filings)

EIN.: 000000000 | State of Incorp.: D8 | Fiscal Year End: 0331
Type: 6-K | Act: 34 | File No.: 001-38773 | Film No.: 25781470
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)